What Most Clinics Won't Tell You About Breast Cancer

What if you could detect and treat breast cancer without surgery, radiation, or high-dose chemo — by catching it earlier than anyone else?In this breakthrough episode, Dr. Dino Prato, founder of Envita Medical Centers, reveals the layered early detection system and precision-based strategies used by less than 1% of doctors. From blood-based multi-cancer testing to cryoablation, this is a new roadmap for prevention, early treatment, and long-term remission.🎯 What You’ll Learn:How a simple blood test (ctDNA + CTC) can screen for 50+ cancers, including breastWhy layering signals (imaging + molecular testing) leads to earlier and more accurate detectionHow cryoablation can remove small tumors without surgeryThe role of methylation scores, immune priming, and antigen visibilityHow to track remission through biomarkers — long before tumors returnWhat most doctors miss: the connection between infections, toxins, and immune dysfunctionWhy breast cancer doesn’t always start with genetics — and what you can do about it“When you use precision tools — not guesswork — you can treat earlier, avoid overtreatment, and restore the body’s immune function.”Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493